These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35739542)

  • 21. Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model.
    Nguyen CM; Bounthavong M; Mendes MA; Christopher ML; Tran JN; Kazerooni R; Morreale AP
    Pharmacoeconomics; 2012 Jul; 30(7):575-93. PubMed ID: 22640174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fractional exhaled nitric oxide and eosinophil count in induced sputum to guide the management of children with asthma: a cost-utility analysis.
    Buendía JA; Guerrero Patiño D; Sánchez Caraballo JM
    BMC Pulm Med; 2022 Jun; 22(1):257. PubMed ID: 35765011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of pembrolizumab for treatment of platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma in China: an economic analysis based on a randomised, open-label, phase III trial.
    Xin W; Ding H; Fang Q; Zheng X; Tong Y; Xu G; Yang G
    BMJ Open; 2020 Dec; 10(12):e038867. PubMed ID: 33371020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-Utility Analysis of the Integrated Care Models for the Management of Hypertension Patients: A Quasi-Experiment in Southwest Rural China.
    Ke X; Zhang L; Tang W
    Front Public Health; 2021; 9():727829. PubMed ID: 34966712
    [No Abstract]   [Full Text] [Related]  

  • 26. Behavioral Economics Interventions to Improve Outpatient Antibiotic Prescribing for Acute Respiratory Infections: a Cost-Effectiveness Analysis.
    Gong CL; Zangwill KM; Hay JW; Meeker D; Doctor JN
    J Gen Intern Med; 2019 Jun; 34(6):846-854. PubMed ID: 29740788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-utility analysis of prenatal supplementation with long-chain n-3 fatty acids to reduce the incidence of wheezing and asthma in neonates.
    Buendia JA; Guerrero-Patino D; Zuluaga A
    J Asthma; 2024 Mar; ():1-9. PubMed ID: 38427828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-Effectiveness of Total Hip Arthroplasty Versus Nonoperative Management in Normal, Overweight, Obese, Severely Obese, Morbidly Obese, and Super Obese Patients: A Markov Model.
    Ponnusamy KE; Vasarhelyi EM; McCalden RW; Somerville LE; Marsh JD
    J Arthroplasty; 2018 Dec; 33(12):3629-3636. PubMed ID: 30266324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic analysis of continuous antibiotic prophylaxis for prevention of urinary tract infections in infants with high-grade hydronephrosis.
    Tu HY; Pemberton J; Lorenzo AJ; Braga LH
    J Pediatr Urol; 2015 Oct; 11(5):247.e1-8. PubMed ID: 26174147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Seven-year cost-effectiveness of ProDisc-C total disc replacement: results from investigational device exemption and post-approval studies.
    Radcliff K; Lerner J; Yang C; Bernard T; Zigler JE
    J Neurosurg Spine; 2016 May; 24(5):760-8. PubMed ID: 26824587
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-utility of first-line actinic keratosis treatments in Finland.
    Soini EJ; Hallinen T; Sokka AL; Saarinen K
    Adv Ther; 2015 May; 32(5):455-76. PubMed ID: 26006101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-utility analysis of the inhaled steroids available in a developing country for the management of pediatric patients with persistent asthma.
    Rodríguez-Martínez CE; Sossa-Briceño MP; Castro-Rodriguez JA
    J Asthma; 2013 May; 50(4):410-8. PubMed ID: 23356720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-Effectiveness and Cost-Utility of a Home-Based Exercise Program in Geriatric Patients with Cognitive Impairment.
    Eckert T; Wronski P; Bongartz M; Ullrich P; Abel B; Kiss R; Wensing M; Koetsenruijter J; Hauer K
    Gerontology; 2021; 67(2):220-232. PubMed ID: 33503629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Types of urethral catheter for reducing symptomatic urinary tract infections in hospitalised adults requiring short-term catheterisation: multicentre randomised controlled trial and economic evaluation of antimicrobial- and antiseptic-impregnated urethral catheters (the CATHETER trial).
    Pickard R; Lam T; Maclennan G; Starr K; Kilonzo M; McPherson G; Gillies K; McDonald A; Walton K; Buckley B; Glazener C; Boachie C; Burr J; Norrie J; Vale L; Grant A; N'dow J
    Health Technol Assess; 2012 Nov; 16(47):1-197. PubMed ID: 23199586
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-utility analysis of intravenous immunoglobulin for the treatment of steroid-refractory dermatomyositis in Thailand.
    Bamrungsawad N; Chaiyakunapruk N; Upakdee N; Pratoomsoot C; Sruamsiri R; Dilokthornsakul P
    Pharmacoeconomics; 2015 May; 33(5):521-31. PubMed ID: 25774016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost Utility of Intermittent Inhaled Corticosteroids in Preschoolers with Viral-Triggered Wheeze.
    Buendía JA; Guerrero Patiño D; Giraldo Ramírez JE
    Pediatr Allergy Immunol Pulmonol; 2022 Mar; 35(1):36-42. PubMed ID: 35320007
    [No Abstract]   [Full Text] [Related]  

  • 39. Sedative-hypnotic medicines and falls in community-dwelling older adults: a cost-effectiveness (decision-tree) analysis from a US Medicare perspective.
    Tannenbaum C; Diaby V; Singh D; Perreault S; Luc M; Vasiliadis HM
    Drugs Aging; 2015 Apr; 32(4):305-14. PubMed ID: 25825121
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.